Details of the Drug-Related molecule(s) Interaction Atlas

General Information of Drug (ID: DMKB9FI)

• Drug Name: Benzoic Acid Drug Info
• Synonyms: Phenylformate; benzoate anion; Benzoic acid, ion(1-); 766-76-7; Benzeneformate; Tennplas; Phenylcarboxylate; Benzenemethanoate; Retarded BA; Benzenecarboxylate; Phenyl carboxylic acid; benzoic acid anion; Oracyclic acid; 4-Carboxybenzenide; Benzene formic acid; AC1Q1HDY; AC1Q22CA; AC1L18SS; GTPL4565; DTXSID4043771; CHEBI:16150; BDBM36181; CTK2H9612; WPYMKLBDIGXBTP-UHFFFAOYSA-M; STL483236; ZINC328578076; NCGC00247905-01; ZB000218; CJ-00025; LS-190261; 3230-EP2374454A1; 3230-EP2372017A1; 3230-EP2316825A1; 3230-EP2316457A1

Indication

Disease Entry	ICD 11	Status	REF
Alopecia areata	ED70.2	Approved	[1]
Dermatomyositis	4A41.0	Approved	[2]
Fungal infection	1F29-1F2F	Approved	[3]
Mycoses	1F2Z	Approved	[4]
Ornithine transcarbamylase deficiency	5C50.AY	Approved	[5]
Peyronie disease		Investigative	[6]
Scleroderma	4A42	Investigative	[7]

• Cross-matching ID:
  PubChem CID: 243
  ChEBI ID: CHEBI:30746
  CAS Number: CAS 65-85-0
  TTD Drug ID: DMKB9FI
  VARIDT Drug ID: DR00703

Molecule-Related Drug Atlas

Drug(s) Targeting Ras-related protein Rab-9A (RAB9A)

Drug Name	Drug ID	Indication	ICD 11	Highest Status	REF
Guanosine-5'-Diphosphate	DM0MUKQ	Discovery agent	N.A.	Investigative	[8]

Drug(s) Transported By Sodium-coupled monocarboxylate transporter 2 (SLC5A12)

Drug Name	Drug ID	Indication	ICD 11	Highest Status	REF
Salicyclic acid	DM2F8XZ	Acne vulgaris	ED80	Approved	[9]
Gamma Hydroxybutyric Acid	DMGBKVD	Narcolepsy	7A20	Approved	[9]

Drug(s) Affected By Glutathione S-transferase A1 (GSTA1)

Drug Name	Drug ID	Indication	ICD 11	Highest Status	REF
Artemisinin	DMOY7W3	Malaria	1F40-1F45	Approved	[14]
Progesterone	DMUY35B	Amenorrhea	GA20.0	Approved	[15]
Thiotepa	DMIZKOP	Breast cancer	2C60-2C65	Approved	[16]
Phenytoin	DMNOKBV	Epilepsy	8A60-8A68	Approved	[17]
Acetaminophen	DMUIE76	Allergic rhinitis	CA08.0	Approved	[18]
Ethacrynic acid	DM60QMR	Edema	MG29	Approved	[19]
Cisplatin	DMRHGI9	Adenocarcinoma	2D40	Approved	[20]
Busulfan	DMXYJ9C	Chronic myelogenous leukaemia	2A20.0	Approved	[21]
Hydrogen peroxide	DM1NG5W	Infectious disease	1A00-CA43.1	Approved	[22]
Methotrexate	DM2TEOL	Anterior urethra cancer		Approved	[23]

Drug(s) Affected By Nitric oxide synthase 3 (NOS3)

Drug Name	Drug ID	Indication	ICD 11	Highest Status	REF
Doxorubicin	DMVP5YE	Acute myelogenous leukaemia	2A41	Approved	[24]
Ciclosporin	DMAZJFX	Graft-versus-host disease	4B24	Approved	[25]
Bosentan	DMIOGBU	Pulmonary arterial hypertension	BB01.0	Approved	[26]
Hydrogen peroxide	DM1NG5W	Infectious disease	1A00-CA43.1	Approved	[27]
Methotrexate	DM2TEOL	Anterior urethra cancer		Approved	[23]
Simvastatin	DM30SGU	Arteriosclerosis	BD40	Approved	[28]
Quercetin	DM3NC4M	Obesity	5B81	Approved	[29]
Troglitazone	DM3VFPD	Diabetic complication	5A2Y	Approved	[30]
Fructose	DM43AN2	Vomiting	MD90	Approved	[31]
Tretinoin	DM49DUI	Acne vulgaris	ED80	Approved	[32]

Drug(s) Affected By Metallothionein-2 (MT2A)

Drug Name	Drug ID	Indication	ICD 11	Highest Status	REF
Cisplatin	DMRHGI9	Adenocarcinoma	2D40	Approved	[33]
Cannabidiol	DM0659E	Dravet syndrome	8A61.11	Approved	[34]
Hydrogen peroxide	DM1NG5W	Infectious disease	1A00-CA43.1	Approved	[35]
Deoxycholic acid	DM3GYAL	Subcutaneous fat disorder	EF02	Approved	[36]
Quercetin	DM3NC4M	Obesity	5B81	Approved	[37]
Troglitazone	DM3VFPD	Diabetic complication	5A2Y	Approved	[38]
Acetic Acid, Glacial	DM4SJ5Y	infection in the ear canal	AA0Y	Approved	[39]
Arsenic trioxide	DM61TA4	Acute lymphoblastic leukaemia	2A85	Approved	[40]
Marinol	DM70IK5	Anorexia nervosa cachexia	6B80	Approved	[41]
Cidofovir	DMA13GD	Cytomegalovirus infection	1D82	Approved	[42]

Drug(s) Affected By Metallothionein-1A (MT1A)

Drug Name	Drug ID	Indication	ICD 11	Highest Status	REF
Cisplatin	DMRHGI9	Adenocarcinoma	2D40	Approved	[33]
Salicyclic acid	DM2F8XZ	Acne vulgaris	ED80	Approved	[43]
Arsenic trioxide	DM61TA4	Acute lymphoblastic leukaemia	2A85	Approved	[44]
Marinol	DM70IK5	Anorexia nervosa cachexia	6B80	Approved	[45]
Valproate	DMCFE9I	Epilepsy	8A60-8A68	Approved	[46]
Zoledronate	DMIXC7G	Adenocarcinoma	2D40	Approved	[47]
Sodium lauryl sulfate	DMLJ634	Constipation	DD91.1	Approved	[43]
Dexamethasone	DMMWZET	Acute adrenal insufficiency		Approved	[48]
Cupric Sulfate	DMP0NFQ	Fungal infection	1F29-1F2F	Approved	[49]
Decitabine	DMQL8XJ	Acute myelogenous leukaemia	2A41	Approved	[50]

Drug(s) Affected By Transcription factor MafG (MAFG)

Drug Name	Drug ID	Indication	ICD 11	Highest Status	REF
Cannabidiol	DM0659E	Dravet syndrome	8A61.11	Approved	[51]
Hydrogen peroxide	DM1NG5W	Infectious disease	1A00-CA43.1	Approved	[35]
Quercetin	DM3NC4M	Obesity	5B81	Approved	[52]
Tretinoin	DM49DUI	Acne vulgaris	ED80	Approved	[53]
Nefazodone	DM4ZS8M	Major depressive disorder	6A70.3	Approved	[54]
Leflunomide	DMR8ONJ	Arthritis	FA20	Approved	[55]
Clodronate	DM9Y6X7	Hypercalcaemia	5B91.0	Approved	[42]
Ciclosporin	DMAZJFX	Graft-versus-host disease	4B24	Approved	[56]
Disulfiram	DMCL2OK	Alcohol dependence	6C40.2	Approved	[10]
Valproate	DMCFE9I	Epilepsy	8A60-8A68	Approved	[46]

Drug(s) Affected By Aldo-keto reductase family 1 member B10 (AKR1B10)

Drug Name	Drug ID	Indication	ICD 11	Highest Status	REF
Hydrogen peroxide	DM1NG5W	Infectious disease	1A00-CA43.1	Approved	[57]
Clavulanate	DM2FGRT	Bacteremia	1A73	Approved	[58]
Quercetin	DM3NC4M	Obesity	5B81	Approved	[52]
Troglitazone	DM3VFPD	Diabetic complication	5A2Y	Approved	[59]
Rifampicin	DM5DSFZ	Non-insulin dependent diabetes	5A11	Approved	[60]
Isoniazid	DM5JVS3	Latent tuberculosis infection		Approved	[61]
Hydroquinone	DM6AVR4	Melasma	ED60.1	Approved	[62]
Reserpine	DM6VM38	Hypertension	BA00-BA04	Approved	[63]
Ciclosporin	DMAZJFX	Graft-versus-host disease	4B24	Approved	[64]
Disulfiram	DMCL2OK	Alcohol dependence	6C40.2	Approved	[10]

Drug(s) Affected By Glutathione reductase, mitochondrial (GSR)

Drug Name	Drug ID	Indication	ICD 11	Highest Status	REF
Cisplatin	DMRHGI9	Adenocarcinoma	2D40	Approved	[65]
Ketoprofen	DMRKXPT	Bursitis		Approved	[26]
Cannabidiol	DM0659E	Dravet syndrome	8A61.11	Approved	[66]
Hydrogen peroxide	DM1NG5W	Infectious disease	1A00-CA43.1	Approved	[67]
Clavulanate	DM2FGRT	Bacteremia	1A73	Approved	[58]
Quercetin	DM3NC4M	Obesity	5B81	Approved	[68]
obeticholic acid	DM3Q1SM	Primary biliary cholangitis	DB96.1	Approved	[69]
Tretinoin	DM49DUI	Acne vulgaris	ED80	Approved	[70]
Acetic Acid, Glacial	DM4SJ5Y	infection in the ear canal	AA0Y	Approved	[39]
Arsenic trioxide	DM61TA4	Acute lymphoblastic leukaemia	2A85	Approved	[71]

Drug(s) Affected By Ferritin light chain (FTL)

Drug Name	Drug ID	Indication	ICD 11	Highest Status	REF
Cannabidiol	DM0659E	Dravet syndrome	8A61.11	Approved	[51]
Hydrogen peroxide	DM1NG5W	Infectious disease	1A00-CA43.1	Approved	[35]
Selenium	DM25CGV	N. A.	N. A.	Approved	[72]
TECFIDERA	DM2OVDT	Multiple sclerosis	8A40	Approved	[73]
Tretinoin	DM49DUI	Acne vulgaris	ED80	Approved	[74]
Arsenic trioxide	DM61TA4	Acute lymphoblastic leukaemia	2A85	Approved	[75]
Disulfiram	DMCL2OK	Alcohol dependence	6C40.2	Approved	[10]
Valproate	DMCFE9I	Epilepsy	8A60-8A68	Approved	[76]
Ivermectin	DMDBX5F	Intestinal strongyloidiasis due to nematode parasite	1F6B	Approved	[77]
Ethanol	DMDRQZU	Chronic pain	MG30	Approved	[78]

Drug(s) Affected By Heme oxygenase 1 (HMOX1)

Drug Name	Drug ID	Indication	ICD 11	Highest Status	REF
Dexamethasone	DMMWZET	Acute adrenal insufficiency		Approved	[79]
Cannabidiol	DM0659E	Dravet syndrome	8A61.11	Approved	[80]
Pantothenic acid	DM091H2	Vitamin deficiency	5B55-5B71	Approved	[81]
Verapamil	DMA7PEW	Angina pectoris	BA40	Approved	[82]
Fulvestrant	DM0YZC6	Breast cancer	2C60-2C65	Approved	[83]
Hydrogen peroxide	DM1NG5W	Infectious disease	1A00-CA43.1	Approved	[84]
Selenium	DM25CGV	N. A.	N. A.	Approved	[85]
TECFIDERA	DM2OVDT	Multiple sclerosis	8A40	Approved	[86]
Sulindac	DM2QHZU	Acute myelogenous leukaemia	2A41	Approved	[87]
Methotrexate	DM2TEOL	Anterior urethra cancer		Approved	[88]

Drug(s) Affected By Glucose-6-phosphate 1-dehydrogenase (G6PD)

Drug Name	Drug ID	Indication	ICD 11	Highest Status	REF
Acetaminophen	DMUIE76	Allergic rhinitis	CA08.0	Approved	[89]
Cyclophosphamide	DM4O2Z7	Advanced cancer	2A00-2F9Z	Approved	[26]
Cannabidiol	DM0659E	Dravet syndrome	8A61.11	Approved	[90]
Fulvestrant	DM0YZC6	Breast cancer	2C60-2C65	Approved	[91]
Hydrogen peroxide	DM1NG5W	Infectious disease	1A00-CA43.1	Approved	[67]
Clavulanate	DM2FGRT	Bacteremia	1A73	Approved	[58]
Quercetin	DM3NC4M	Obesity	5B81	Approved	[52]
Tretinoin	DM49DUI	Acne vulgaris	ED80	Approved	[92]
Isotretinoin	DM4QTBN	Acne vulgaris	ED80	Approved	[93]
Isoniazid	DM5JVS3	Latent tuberculosis infection		Approved	[94]

Drug(s) Affected By Aldo-keto reductase family 1 member B1 (AKR1B1)

Drug Name	Drug ID	Indication	ICD 11	Highest Status	REF
Quercetin	DM3NC4M	Obesity	5B81	Approved	[52]
Tretinoin	DM49DUI	Acne vulgaris	ED80	Approved	[95]
Arsenic trioxide	DM61TA4	Acute lymphoblastic leukaemia	2A85	Approved	[96]
Glutathione	DMAHMT9	Human immunodeficiency virus infection	1C62	Approved	[97]
Ciclosporin	DMAZJFX	Graft-versus-host disease	4B24	Approved	[98]
Disulfiram	DMCL2OK	Alcohol dependence	6C40.2	Approved	[10]
Valproate	DMCFE9I	Epilepsy	8A60-8A68	Approved	[46]
Ivermectin	DMDBX5F	Intestinal strongyloidiasis due to nematode parasite	1F6B	Approved	[77]
Zoledronate	DMIXC7G	Adenocarcinoma	2D40	Approved	[99]
Temozolomide	DMKECZD	Adenocarcinoma	2D40	Approved	[100]

Drug(s) Affected By NAD(P)H dehydrogenase 1 (NQO1)

Drug Name	Drug ID	Indication	ICD 11	Highest Status	REF
Cisplatin	DMRHGI9	Adenocarcinoma	2D40	Approved	[42]
Doxorubicin	DMVP5YE	Acute myelogenous leukaemia	2A41	Approved	[101]
Cannabidiol	DM0659E	Dravet syndrome	8A61.11	Approved	[51]
Hydrogen peroxide	DM1NG5W	Infectious disease	1A00-CA43.1	Approved	[102]
TECFIDERA	DM2OVDT	Multiple sclerosis	8A40	Approved	[103]
Sulindac	DM2QHZU	Acute myelogenous leukaemia	2A41	Approved	[104]
Simvastatin	DM30SGU	Arteriosclerosis	BD40	Approved	[105]
Lapatinib	DM3BH1Y	Breast cancer	2C60-2C65	Approved	[106]
Quercetin	DM3NC4M	Obesity	5B81	Approved	[107]
Rofecoxib	DM3P5DA	Osteoarthritis	FA00-FA05	Approved	[108]

Drug(s) Affected By Ferrochelatase, mitochondrial (FECH)

Drug Name	Drug ID	Indication	ICD 11	Highest Status	REF
Hydrogen peroxide	DM1NG5W	Infectious disease	1A00-CA43.1	Approved	[109]
Selenium	DM25CGV	N. A.	N. A.	Approved	[72]
Isoniazid	DM5JVS3	Latent tuberculosis infection		Approved	[110]
Clodronate	DM9Y6X7	Hypercalcaemia	5B91.0	Approved	[42]
Cidofovir	DMA13GD	Cytomegalovirus infection	1D82	Approved	[42]
Disulfiram	DMCL2OK	Alcohol dependence	6C40.2	Approved	[10]
Valproate	DMCFE9I	Epilepsy	8A60-8A68	Approved	[76]
Ifosfamide	DMCT3I8	Adult central nervous system germ cell tumor		Approved	[42]
Zoledronate	DMIXC7G	Adenocarcinoma	2D40	Approved	[99]
Temozolomide	DMKECZD	Adenocarcinoma	2D40	Approved	[100]

Drug(s) Affected By Aldo-keto reductase family 1 member C3 (AKR1C3)

Drug Name	Drug ID	Indication	ICD 11	Highest Status	REF
Doxorubicin	DMVP5YE	Acute myelogenous leukaemia	2A41	Approved	[111]
Meclofenamic acid	DM05FXR	Ankylosing spondylitis	FA92.0	Approved	[112]
Diazepam	DM08E9O	Alcohol withdrawal		Approved	[113]
Levonorgestrel	DM1DP7T	Atypical endometrial hyperplasia		Approved	[114]
Desogestrel	DM27U4Y	Contraception	QA21	Approved	[114]
Salicyclic acid	DM2F8XZ	Acne vulgaris	ED80	Approved	[112]
Sulindac	DM2QHZU	Acute myelogenous leukaemia	2A41	Approved	[112]
Simvastatin	DM30SGU	Arteriosclerosis	BD40	Approved	[115]
Quercetin	DM3NC4M	Obesity	5B81	Approved	[116]
Tretinoin	DM49DUI	Acne vulgaris	ED80	Approved	[53]

Drug(s) Affected By NADP-dependent malic enzyme (ME1)

Drug Name	Drug ID	Indication	ICD 11	Highest Status	REF
Cannabidiol	DM0659E	Dravet syndrome	8A61.11	Approved	[51]
Hydrogen peroxide	DM1NG5W	Infectious disease	1A00-CA43.1	Approved	[35]
Selenium	DM25CGV	N. A.	N. A.	Approved	[72]
Clavulanate	DM2FGRT	Bacteremia	1A73	Approved	[58]
Tretinoin	DM49DUI	Acne vulgaris	ED80	Approved	[95]
Isotretinoin	DM4QTBN	Acne vulgaris	ED80	Approved	[93]
Arsenic trioxide	DM61TA4	Acute lymphoblastic leukaemia	2A85	Approved	[117]
Clodronate	DM9Y6X7	Hypercalcaemia	5B91.0	Approved	[42]
Ciclosporin	DMAZJFX	Graft-versus-host disease	4B24	Approved	[42]
Disulfiram	DMCL2OK	Alcohol dependence	6C40.2	Approved	[10]

Drug(s) Affected By Glutamate--cysteine ligase catalytic subunit (GCLC)

Drug Name	Drug ID	Indication	ICD 11	Highest Status	REF
Cannabidiol	DM0659E	Dravet syndrome	8A61.11	Approved	[51]
Hydrogen peroxide	DM1NG5W	Infectious disease	1A00-CA43.1	Approved	[84]
Methimazole	DM25FL8	Hyperthyroidism	5A02	Approved	[118]
Clavulanate	DM2FGRT	Bacteremia	1A73	Approved	[58]
Sulindac	DM2QHZU	Acute myelogenous leukaemia	2A41	Approved	[119]
Quercetin	DM3NC4M	Obesity	5B81	Approved	[120]
Troglitazone	DM3VFPD	Diabetic complication	5A2Y	Approved	[121]
Tretinoin	DM49DUI	Acne vulgaris	ED80	Approved	[95]
Acetic Acid, Glacial	DM4SJ5Y	infection in the ear canal	AA0Y	Approved	[122]
Arsenic trioxide	DM61TA4	Acute lymphoblastic leukaemia	2A85	Approved	[123]

Drug(s) Affected By Glutamate--cysteine ligase regulatory subunit (GCLM)

Drug Name	Drug ID	Indication	ICD 11	Highest Status	REF
Cannabidiol	DM0659E	Dravet syndrome	8A61.11	Approved	[51]
Hydrogen peroxide	DM1NG5W	Infectious disease	1A00-CA43.1	Approved	[124]
Clavulanate	DM2FGRT	Bacteremia	1A73	Approved	[58]
Quercetin	DM3NC4M	Obesity	5B81	Approved	[125]
Tretinoin	DM49DUI	Acne vulgaris	ED80	Approved	[95]
Isotretinoin	DM4QTBN	Acne vulgaris	ED80	Approved	[93]
Acetic Acid, Glacial	DM4SJ5Y	infection in the ear canal	AA0Y	Approved	[39]
Isoniazid	DM5JVS3	Latent tuberculosis infection		Approved	[126]
Arsenic trioxide	DM61TA4	Acute lymphoblastic leukaemia	2A85	Approved	[117]
Hydroquinone	DM6AVR4	Melasma	ED60.1	Approved	[127]

Drug(s) Affected By 6-phosphogluconate dehydrogenase, decarboxylating (PGD)

Drug Name	Drug ID	Indication	ICD 11	Highest Status	REF
Quercetin	DM3NC4M	Obesity	5B81	Approved	[52]
Tretinoin	DM49DUI	Acne vulgaris	ED80	Approved	[128]
Isotretinoin	DM4QTBN	Acne vulgaris	ED80	Approved	[93]
Arsenic trioxide	DM61TA4	Acute lymphoblastic leukaemia	2A85	Approved	[75]
Ciclosporin	DMAZJFX	Graft-versus-host disease	4B24	Approved	[56]
Disulfiram	DMCL2OK	Alcohol dependence	6C40.2	Approved	[10]
Valproate	DMCFE9I	Epilepsy	8A60-8A68	Approved	[46]
Ivermectin	DMDBX5F	Intestinal strongyloidiasis due to nematode parasite	1F6B	Approved	[77]
Methylene blue	DMJAPE7	Acquired methemoglobinemia	3A93	Approved	[129]
Temozolomide	DMKECZD	Adenocarcinoma	2D40	Approved	[100]

Drug(s) Affected By Aldo-keto reductase family 1 member C1 (AKR1C1)

Drug Name	Drug ID	Indication	ICD 11	Highest Status	REF
Progesterone	DMUY35B	Amenorrhea	GA20.0	Approved	[130]
Meclofenamic acid	DM05FXR	Ankylosing spondylitis	FA92.0	Approved	[112]
Diazepam	DM08E9O	Alcohol withdrawal		Approved	[113]
Hydrogen peroxide	DM1NG5W	Infectious disease	1A00-CA43.1	Approved	[131]
Salicyclic acid	DM2F8XZ	Acne vulgaris	ED80	Approved	[112]
Sulindac	DM2QHZU	Acute myelogenous leukaemia	2A41	Approved	[112]
Simvastatin	DM30SGU	Arteriosclerosis	BD40	Approved	[132]
Glimepiride	DM5FSJA	Diabetic complication	5A2Y	Approved	[133]
Ethacrynic acid	DM60QMR	Edema	MG29	Approved	[131]
Aspirin	DM672AH	Acute coronary syndrome	BA41	Approved	[112]

Drug(s) Affected By Prostaglandin reductase 1 (PTGR1)

Drug Name	Drug ID	Indication	ICD 11	Highest Status	REF
Cannabidiol	DM0659E	Dravet syndrome	8A61.11	Approved	[51]
Hydrogen peroxide	DM1NG5W	Infectious disease	1A00-CA43.1	Approved	[57]
Quercetin	DM3NC4M	Obesity	5B81	Approved	[52]
Tretinoin	DM49DUI	Acne vulgaris	ED80	Approved	[95]
Arsenic trioxide	DM61TA4	Acute lymphoblastic leukaemia	2A85	Approved	[75]
Ibuprofen	DM8VCBE	Dysmenorrhea	GA34.3	Approved	[134]
Ciclosporin	DMAZJFX	Graft-versus-host disease	4B24	Approved	[56]
Disulfiram	DMCL2OK	Alcohol dependence	6C40.2	Approved	[10]
Valproate	DMCFE9I	Epilepsy	8A60-8A68	Approved	[135]
Ivermectin	DMDBX5F	Intestinal strongyloidiasis due to nematode parasite	1F6B	Approved	[77]

Drug(s) Affected By Sulfiredoxin-1 (SRXN1)

Drug Name	Drug ID	Indication	ICD 11	Highest Status	REF
Cannabidiol	DM0659E	Dravet syndrome	8A61.11	Approved	[51]
Hydrogen peroxide	DM1NG5W	Infectious disease	1A00-CA43.1	Approved	[22]
Troglitazone	DM3VFPD	Diabetic complication	5A2Y	Approved	[121]
Tretinoin	DM49DUI	Acne vulgaris	ED80	Approved	[53]
Isoniazid	DM5JVS3	Latent tuberculosis infection		Approved	[61]
Ethacrynic acid	DM60QMR	Edema	MG29	Approved	[136]
Arsenic trioxide	DM61TA4	Acute lymphoblastic leukaemia	2A85	Approved	[137]
Ibuprofen	DM8VCBE	Dysmenorrhea	GA34.3	Approved	[42]
Leflunomide	DMR8ONJ	Arthritis	FA20	Approved	[55]
Clodronate	DM9Y6X7	Hypercalcaemia	5B91.0	Approved	[42]

Drug(s) Affected By Myeloperoxidase (MPO)

Drug Name	Drug ID	Indication	ICD 11	Highest Status	REF
Dapsone	DM4LT8A	Acne vulgaris	ED80	Approved	[26]
Cisplatin	DMRHGI9	Adenocarcinoma	2D40	Approved	[138]
Ibuprofen	DM8VCBE	Dysmenorrhea	GA34.3	Approved	[26]
Sulfamethoxazole	DMB08GE	Acute otitis media	AB00	Approved	[26]
Hydrogen peroxide	DM1NG5W	Infectious disease	1A00-CA43.1	Approved	[139]
Salicyclic acid	DM2F8XZ	Acne vulgaris	ED80	Approved	[140]
Simvastatin	DM30SGU	Arteriosclerosis	BD40	Approved	[141]
Penicillamine	DM40EF6	Cystinuria	5C60.2	Approved	[142]
Tretinoin	DM49DUI	Acne vulgaris	ED80	Approved	[143]
Propylthiouracil	DM6D7N8	Hyperthyroidism	5A02	Approved	[144]

Drug(s) Affected By Catalase (CAT)

Drug Name	Drug ID	Indication	ICD 11	Highest Status	REF
Hydrogen peroxide	DM1NG5W	Infectious disease	1A00-CA43.1	Approved	[102]
Cisplatin	DMRHGI9	Adenocarcinoma	2D40	Approved	[145]
Haloperidol	DM96SE0	Delirium		Approved	[26]
Cannabidiol	DM0659E	Dravet syndrome	8A61.11	Approved	[66]
Selenium	DM25CGV	N. A.	N. A.	Approved	[146]
Methimazole	DM25FL8	Hyperthyroidism	5A02	Approved	[147]
Citalopram	DM2G9AE	Acute coronary syndrome	BA41	Approved	[148]
Methotrexate	DM2TEOL	Anterior urethra cancer		Approved	[149]
Simvastatin	DM30SGU	Arteriosclerosis	BD40	Approved	[150]
Quercetin	DM3NC4M	Obesity	5B81	Approved	[52]

Drug(s) Affected By Myc proto-oncogene protein (MYC)

Drug Name	Drug ID	Indication	ICD 11	Highest Status	REF
Estradiol	DMUNTE3	Acne vulgaris	ED80	Approved	[151]
Sertraline	DM0FB1J	Coronary heart disease	BA80.Z	Approved	[152]
Fulvestrant	DM0YZC6	Breast cancer	2C60-2C65	Approved	[153]
Gefitinib	DM15F0X	Colon adenocarcinoma		Approved	[154]
Hydrogen peroxide	DM1NG5W	Infectious disease	1A00-CA43.1	Approved	[155]
Selenium	DM25CGV	N. A.	N. A.	Approved	[156]
Ribavirin	DMEYLH9	Hepatitis C virus infection	1E51.1	Approved	[157]
Trametinib	DM2JGQ3	Melanoma	2C30	Approved	[158]
Sulindac	DM2QHZU	Acute myelogenous leukaemia	2A41	Approved	[159]
Methotrexate	DM2TEOL	Anterior urethra cancer		Approved	[149]

Drug(s) Affected By Interleukin-1 alpha (IL1A)

Drug Name	Drug ID	Indication	ICD 11	Highest Status	REF
Cannabidiol	DM0659E	Dravet syndrome	8A61.11	Approved	[34]
Primidone	DM0WX6I	Epilepsy	8A60-8A68	Approved	[160]
Fexofenadine	DM17ONX	Allergic rhinitis	CA08.0	Approved	[160]
Hydrogen peroxide	DM1NG5W	Infectious disease	1A00-CA43.1	Approved	[161]
Clavulanate	DM2FGRT	Bacteremia	1A73	Approved	[160]
Methotrexate	DM2TEOL	Anterior urethra cancer		Approved	[149]
Quercetin	DM3NC4M	Obesity	5B81	Approved	[162]
Rofecoxib	DM3P5DA	Osteoarthritis	FA00-FA05	Approved	[160]
Troglitazone	DM3VFPD	Diabetic complication	5A2Y	Approved	[38]
Tretinoin	DM49DUI	Acne vulgaris	ED80	Approved	[95]

Drug(s) Affected By Interleukin-8 (CXCL8)

Drug Name	Drug ID	Indication	ICD 11	Highest Status	REF
Hydrocortisone	DMGEMB7	Acne vulgaris	ED80	Approved	[163]
Nicotine	DMWX5CO	Lung cancer	2C25.0	Approved	[164]
Cannabidiol	DM0659E	Dravet syndrome	8A61.11	Approved	[165]
Pantothenic acid	DM091H2	Vitamin deficiency	5B55-5B71	Approved	[81]
Mechlorethamine	DM0CVXA	Chronic myelogenous leukaemia	2A20.0	Approved	[166]
Fulvestrant	DM0YZC6	Breast cancer	2C60-2C65	Approved	[83]
Fexofenadine	DM17ONX	Allergic rhinitis	CA08.0	Approved	[160]
Hydrogen peroxide	DM1NG5W	Infectious disease	1A00-CA43.1	Approved	[102]
Nitric Oxide	DM1RBYG	Hypertension	BA00-BA04	Approved	[167]
Lumiracoxib	DM1S4AG	Chronic renal failure	GB61.Z	Approved	[160]

Drug(s) Affected By Tyrosine-protein phosphatase non-receptor type 2 (PTPN2)

Drug Name	Drug ID	Indication	ICD 11	Highest Status	REF
Hydrogen peroxide	DM1NG5W	Infectious disease	1A00-CA43.1	Approved	[124]
Acocantherin	DM7JT24	Atrial fibrillation	BC81.3	Approved	[168]
Ciclosporin	DMAZJFX	Graft-versus-host disease	4B24	Approved	[98]
Valproate	DMCFE9I	Epilepsy	8A60-8A68	Approved	[46]
Doxorubicin	DMVP5YE	Acute myelogenous leukaemia	2A41	Approved	[111]
Diphenylpyraline	DMW4X37	Allergic rhinitis	CA08.0	Approved	[169]
Benzo(a)pyrene	DMN7J43	N. A.	N. A.	Phase 1	[170]
PMID28460551-Compound-2	DM4DOUB	N. A.	N. A.	Patented	[171]
PMID28870136-Compound-48	DMPIM9L	N. A.	N. A.	Patented	[124]
Torcetrapib	DMDHYM7	Hyperlipidaemia	5C80	Discontinued in Phase 2	[172]

Drug(s) Affected By Tyrosine-protein phosphatase non-receptor type 1 (PTPN1)

Drug Name	Drug ID	Indication	ICD 11	Highest Status	REF
Arsenic trioxide	DM61TA4	Acute lymphoblastic leukaemia	2A85	Approved	[40]
Calcitriol	DM8ZVJ7	Congenital alopecia	LC30	Approved	[173]
Valproate	DMCFE9I	Epilepsy	8A60-8A68	Approved	[76]
Ivermectin	DMDBX5F	Intestinal strongyloidiasis due to nematode parasite	1F6B	Approved	[77]
Estradiol	DMUNTE3	Acne vulgaris	ED80	Approved	[174]
Vorinostat	DMWMPD4	Adult acute monocytic leukemia		Approved	[175]
Seocalcitol	DMKL9QO	Rickets	5B57	Phase 3	[176]
URSOLIC ACID	DM4SOAW	Metabolic syndrome x	5C50-5D2Z	Phase 2	[177]
DNCB	DMDTVYC	Immune System disease	4A01-4B41	Phase 2	[178]
Benzo(a)pyrene	DMN7J43	N. A.	N. A.	Phase 1	[179]

Drug(s) Affected By G1/S-specific cyclin-D1 (CCND1)

Drug Name	Drug ID	Indication	ICD 11	Highest Status	REF
Indomethacin	DMSC4A7	Bursitis		Approved	[180]
Cannabidiol	DM0659E	Dravet syndrome	8A61.11	Approved	[181]
Beta-carotene	DM0RXBT	Vitamin deficiency	5B55-5B71	Approved	[182]
Fulvestrant	DM0YZC6	Breast cancer	2C60-2C65	Approved	[183]
Gefitinib	DM15F0X	Colon adenocarcinoma		Approved	[184]
Talazoparib	DM1KS78	Breast cancer	2C60-2C65	Approved	[185]
Hydrogen peroxide	DM1NG5W	Infectious disease	1A00-CA43.1	Approved	[186]
Selenium	DM25CGV	N. A.	N. A.	Approved	[72]
Ribavirin	DMEYLH9	Hepatitis C virus infection	1E51.1	Approved	[157]
Sulindac	DM2QHZU	Acute myelogenous leukaemia	2A41	Approved	[187]

Drug(s) Affected By Low molecular weight phosphotyrosine protein phosphatase (ACP1)

Drug Name	Drug ID	Indication	ICD 11	Highest Status	REF
Selenium	DM25CGV	N. A.	N. A.	Approved	[72]
Tretinoin	DM49DUI	Acne vulgaris	ED80	Approved	[188]
Valproate	DMCFE9I	Epilepsy	8A60-8A68	Approved	[46]
Ivermectin	DMDBX5F	Intestinal strongyloidiasis due to nematode parasite	1F6B	Approved	[77]
Aminoglutethimide	DMWFHMZ	Cushing disease	5A70	Approved	[189]
Vorinostat	DMWMPD4	Adult acute monocytic leukemia		Approved	[190]
Vinblastine	DM5TVS3	Advanced cancer	2A00-2F9Z	Approved	[191]
Doxorubicin	DMVP5YE	Acute myelogenous leukaemia	2A41	Approved	[191]
Tocopherol	DMBIJZ6	N. A.	N. A.	Phase 2	[72]
DNCB	DMDTVYC	Immune System disease	4A01-4B41	Phase 2	[178]

Drug(s) Affected By Solute carrier family 15 member 1 (SLC15A1)

Drug Name	Drug ID	Indication	ICD 11	Highest Status	REF
Isotretinoin	DM4QTBN	Acne vulgaris	ED80	Approved	[93]
Rifampicin	DM5DSFZ	Non-insulin dependent diabetes	5A11	Approved	[192]
Repaglinide	DM5SXUV	Diabetic complication	5A2Y	Approved	[193]
Arsenic trioxide	DM61TA4	Acute lymphoblastic leukaemia	2A85	Approved	[155]
Liothyronine	DM6IR3P	Congenital hypothyroidism		Approved	[194]
Ibuprofen	DM8VCBE	Dysmenorrhea	GA34.3	Approved	[195]
Ciclosporin	DMAZJFX	Graft-versus-host disease	4B24	Approved	[56]
Valproate	DMCFE9I	Epilepsy	8A60-8A68	Approved	[196]
Zoledronate	DMIXC7G	Adenocarcinoma	2D40	Approved	[99]
Azathioprine	DMMZSXQ	Lupus nephritis	4A40.0Y	Approved	[197]

Drug(s) Affected By Cytochrome P450 2A6 (CYP2A6)

Drug Name	Drug ID	Indication	ICD 11	Highest Status	REF
Tegafur	DM31ZQM	Solid tumour/cancer	2A00-2F9Z	Approved	[198]
Methoxsalen	DME8FZ9	Cutaneous T-cell lymphoma	2B01	Approved	[199]
Fluorouracil	DMUM7HZ	Adenocarcinoma	2D40	Approved	[200]
Tretinoin	DM49DUI	Acne vulgaris	ED80	Approved	[201]
Acetaminophen	DMUIE76	Allergic rhinitis	CA08.0	Approved	[202]
Progesterone	DMUY35B	Amenorrhea	GA20.0	Approved	[203]
Ifosfamide	DMCT3I8	Adult central nervous system germ cell tumor		Approved	[204]
Valproate	DMCFE9I	Epilepsy	8A60-8A68	Approved	[205]
Letrozole	DMH07Y3	Estrogen-receptor positive breast cancer		Approved	[206]
Nicotine	DMWX5CO	Lung cancer	2C25.0	Approved	[207]

Drug(s) Affected By Cholinesterase (BCHE)

Drug Name	Drug ID	Indication	ICD 11	Highest Status	REF
Cocaine	DMSOX7I	Anaesthesia	9A78.6	Approved	[208]
Tacrine	DM51FY6	Alzheimer disease	8A20	Approved	[209]
Galantamine	DMEO794	Alzheimer disease	8A20	Approved	[210]
Rivastigmine	DMG629M	Alzheimer disease	8A20	Approved	[211]
Donepezil	DMIYG7Z	Advanced cancer	2A00-2F9Z	Approved	[26]
Succinylcholine	DM2ET1M	Plasma cell myeloma	2A83.1	Approved	[212]
Ethopropazine	DM0N3L7	Parkinson disease	8A00.0	Approved	[209]
Dimenhydrinate	DM264B3	Meniere disease	AB31.0	Approved	[213]
Cyclophosphamide	DM4O2Z7	Advanced cancer	2A00-2F9Z	Approved	[214]
Chlorpheniramine	DM5URA2	Allergic rhinitis	CA08.0	Approved	[213]

Drug(s) Affected By Monocarboxylate transporter 1 (SLC16A1)

Drug Name	Drug ID	Indication	ICD 11	Highest Status	REF
Doxorubicin	DMVP5YE	Acute myelogenous leukaemia	2A41	Approved	[111]
Hydrogen peroxide	DM1NG5W	Infectious disease	1A00-CA43.1	Approved	[22]
Tretinoin	DM49DUI	Acne vulgaris	ED80	Approved	[92]
Zidovudine	DM4KI7O	Human immunodeficiency virus infection	1C62	Approved	[215]
Isotretinoin	DM4QTBN	Acne vulgaris	ED80	Approved	[92]
Acetic Acid, Glacial	DM4SJ5Y	infection in the ear canal	AA0Y	Approved	[39]
Panobinostat	DM58WKG	Chronic graft versus host disease		Approved	[216]
Aspirin	DM672AH	Acute coronary syndrome	BA41	Approved	[217]
Marinol	DM70IK5	Anorexia nervosa cachexia	6B80	Approved	[218]
Ciclosporin	DMAZJFX	Graft-versus-host disease	4B24	Approved	[98]

Molecular Interaction Atlas of This Drug

Drug Therapeutic Target (DTT)

DTT Name	DTT ID	UniProt ID	MOA	REF
Ras-related protein Rab-9A (RAB9A)	TT958S6	RAB9A_HUMAN	Inhibitor	[8]

Drug Transporter (DTP)

DTP Name	DTP ID	UniProt ID	MOA	REF
Sodium-coupled monocarboxylate transporter 2 (SLC5A12)	DTM301H	SC5AC_HUMAN	Substrate	[9]

Drug Off-Target (DOT)

DOT Name	DOT ID	UniProt ID	Interaction	REF
6-phosphogluconate dehydrogenase, decarboxylating (PGD)	OTVG296F	6PGD_HUMAN	Gene/Protein Processing	[10]
Aldo-keto reductase family 1 member B1 (AKR1B1)	OTRX72TH	ALDR_HUMAN	Gene/Protein Processing	[10]
Aldo-keto reductase family 1 member B10 (AKR1B10)	OTOA4HTH	AK1BA_HUMAN	Gene/Protein Processing	[10]
Aldo-keto reductase family 1 member C1 (AKR1C1)	OTQKR4CM	AK1C1_HUMAN	Gene/Protein Processing	[10]
Aldo-keto reductase family 1 member C3 (AKR1C3)	OTU2SXBA	AK1C3_HUMAN	Gene/Protein Processing	[10]
Catalase (CAT)	OTHEBX9R	CATA_HUMAN	Gene/Protein Processing	[11]
Cholinesterase (BCHE)	OTOH3WQ9	CHLE_HUMAN	Biotransformations	[12]
Cytochrome P450 2A6 (CYP2A6)	OT52TWG3	CP2A6_HUMAN	Biotransformations	[13]
Ferritin light chain (FTL)	OTYQA8A6	FRIL_HUMAN	Gene/Protein Processing	[10]
Ferrochelatase, mitochondrial (FECH)	OTDWEI6C	HEMH_HUMAN	Gene/Protein Processing	[10]

References

• [1] Benzoic acid and its derivatives as naturally occurring compounds in foods and as additives: Uses, exposure, and controversy. Crit Rev Food Sci Nutr. 2017 Sep 22;57(14):3084-3103.
• [2] Benzoic acid production via cascade biotransformation and coupled fermentation-biotransformation. Biotechnol Bioeng. 2020 Aug;117(8):2340-2350.
• [3] URL: http://www.guidetopharmacology.org Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Ligand id: 4565).
• [4] Synergistic effect of antioxidant system and osmolyte in hydrogen sulfide and salicylic acid crosstalk-induced heat tolerance in maize (Zea mays L.) seedlings. Plant Signal Behav. 2015;10(9):e1051278.
• [5] Ornithine transcarbamylase deficiency: a urea cycle defect. Eur J Paediatr Neurol. 2003;7(3):115-21.
• [6] Safety Assessment of Benzyl Alcohol, Benzoic Acid and its Salts, and Benzyl Benzoate. Int J Toxicol. 2017 Nov/Dec;36(3_suppl):5S-30S.
• [7] The intracellular chloride channel 4 (CLIC4) activates systemic sclerosis fibroblasts. Rheumatology (Oxford). 2021 Sep 1;60(9):4395-4400.
• [8] How many drug targets are there Nat Rev Drug Discov. 2006 Dec;5(12):993-6.
• [9] Sodium-coupled monocarboxylate transporters in normal tissues and in cancer. AAPS J. 2008;10(1):193-9.
• [10] Keratinocyte gene expression profiles discriminate sensitizing and irritating compounds. Toxicol Sci. 2010 Sep;117(1):81-9.
• [11] In vitro effects of quercetin on oxidative stress mediated in human erythrocytes by benzoic acid and citric acid. Folia Biol (Krakow). 2014;62(1):59-66.
• [12] Kinetic characterization of cholinesterases and a therapeutically valuable cocaine hydrolase for their catalytic activities against heroin and its metabolite 6-monoacetylmorphine. Chem Biol Interact. 2018 Sep 25;293:107-114.
• [13] Metabolism of N-nitrosobenzylmethylamine by human cytochrome P-450 enzymes. J Toxicol Environ Health A. 1999 Dec 10;58(7):397-411.
• [14] Inhibition of glutathione S-transferases by antimalarial drugs possible implications for circumventing anticancer drug resistance. Int J Cancer. 2002 Feb 10;97(5):700-5.
• [15] Human glutathione S-transferase A (GSTA) family genes are regulated by steroidogenic factor 1 (SF-1) and are involved in steroidogenesis. FASEB J. 2013 Aug;27(8):3198-208. doi: 10.1096/fj.12-222745. Epub 2013 May 6.
• [16] Polymorphisms of drug-metabolizing enzymes (GST, CYP2B6 and CYP3A) affect the pharmacokinetics of thiotepa and tepa. Br J Clin Pharmacol. 2009 Jan;67(1):50-60. doi: 10.1111/j.1365-2125.2008.03321.x. Epub 2008 Nov 17.
• [17] Effects of phenytoin on glutathione status and oxidative stress biomarker gene mRNA levels in cultured precision human liver slices. Toxicol Sci. 2001 Jan;59(1):118-26.
• [18] Acetaminophen-induced hepatocyte injury: C2-ceramide and oltipraz intervention, hepatocyte nuclear factor 1 and glutathione S-transferase A1 changes. J Appl Toxicol. 2019 Dec;39(12):1640-1650. doi: 10.1002/jat.3881. Epub 2019 Aug 6.
• [19] Antineoplastic drug sensitivity of human MCF-7 breast cancer cells stably transfected with a human alpha class glutathione S-transferase gene. Cancer Res. 1991 Jan 15;51(2):587-94.
• [20] Establishment of cisplatin-resistant ovarian yolk sac tumor cells and investigation of the mechanism of cisplatin resistance using this cell line. Gynecol Obstet Invest. 2011;71(2):104-11. doi: 10.1159/000320744. Epub 2010 Dec 9.
• [21] Overexpression of glutathione S-transferase A1-1 in ECV 304 cells protects against busulfan mediated G2-arrest and induces tissue factor expression. Br J Pharmacol. 2002 Dec;137(7):1100-6. doi: 10.1038/sj.bjp.0704972.
• [22] Global gene expression analysis reveals differences in cellular responses to hydroxyl- and superoxide anion radical-induced oxidative stress in caco-2 cells. Toxicol Sci. 2010 Apr;114(2):193-203. doi: 10.1093/toxsci/kfp309. Epub 2009 Dec 31.
• [23] Global molecular effects of tocilizumab therapy in rheumatoid arthritis synovium. Arthritis Rheumatol. 2014 Jan;66(1):15-23.
• [24] Protective effects of S-carvedilol on doxorubicin-induced damages to human umbilical vein endothelial cells and rats. J Appl Toxicol. 2019 Aug;39(8):1233-1244. doi: 10.1002/jat.3809. Epub 2019 May 7.
• [25] Oxidative stress in kidney transplant patients with calcineurin inhibitor-induced hypertension: effect of ramipril. J Cardiovasc Pharmacol. 2002 Oct;40(4):625-31.
• [26] ADReCS-Target: target profiles for aiding drug safety research and application. Nucleic Acids Res. 2018 Jan 4;46(D1):D911-D917. doi: 10.1093/nar/gkx899.
• [27] Hydrogen peroxide decreases endothelial nitric oxide synthase promoter activity through the inhibition of Sp1 activity. DNA Cell Biol. 2009 Mar;28(3):119-29.
• [28] Simvastatin inhibits cigarette smoking-induced emphysema and pulmonary hypertension in rat lungs. Am J Respir Crit Care Med. 2005 Oct 15;172(8):987-93. doi: 10.1164/rccm.200501-041OC. Epub 2005 Jul 7.
• [29] A blend of polyphenolic compounds explains the stimulatory effect of red wine on human endothelial NO synthase. Nitric Oxide. 2005 Mar;12(2):97-104.
• [30] The thiazolidinedione drug troglitazone up-regulates nitric oxide synthase expression in vascular endothelial cells. J Diabetes Complications. 2006 Sep-Oct;20(5):336-42.
• [31] Fructose induces the inflammatory molecule ICAM-1 in endothelial cells. J Am Soc Nephrol. 2008 Sep;19(9):1712-20.
• [32] Upregulation of nitric oxide production in vascular endothelial cells by all-trans retinoic acid through the phosphoinositide 3-kinase/Akt pathway. Circulation. 2005 Aug 2;112(5):727-36. doi: 10.1161/CIRCULATIONAHA.104.500959. Epub 2005 Jul 25.
• [33] Expression pattern of cisplatin-induced metallothionein isoforms in squamous cell carcinoma. Anticancer Res. 2003 Jan-Feb;23(1A):299-303.
• [34] Cannabidiol enhances cytotoxicity of anti-cancer drugs in human head and neck squamous cell carcinoma. Sci Rep. 2020 Nov 26;10(1):20622. doi: 10.1038/s41598-020-77674-y.
• [35] Gene expression after treatment with hydrogen peroxide, menadione, or t-butyl hydroperoxide in breast cancer cells. Cancer Res. 2002 Nov 1;62(21):6246-54.
• [36] Identification of novel activators of the metal responsive transcription factor (MTF-1) using a gene expression biomarker in a microarray compendium. Metallomics. 2020 Sep 23;12(9):1400-1415. doi: 10.1039/d0mt00071j.
• [37] Expression of antioxidant proteins in human intestinal Caco-2 cells treated with dietary flavonoids. Cancer Lett. 1999 Nov 15;146(2):161-7.
• [38] Increased sensitivity for troglitazone-induced cytotoxicity using a human in vitro co-culture model. Toxicol In Vitro. 2009 Oct;23(7):1387-95.
• [39] Motexafin gadolinium and zinc induce oxidative stress responses and apoptosis in B-cell lymphoma lines. Cancer Res. 2005 Dec 15;65(24):11676-88.
• [40] Chronic occupational exposure to arsenic induces carcinogenic gene signaling networks and neoplastic transformation in human lung epithelial cells. Toxicol Appl Pharmacol. 2012 Jun 1;261(2):204-16.
• [41] JunD is involved in the antiproliferative effect of Delta9-tetrahydrocannabinol on human breast cancer cells. Oncogene. 2008 Aug 28;27(37):5033-44.
• [42] Transcriptomics hit the target: monitoring of ligand-activated and stress response pathways for chemical testing. Toxicol In Vitro. 2015 Dec 25;30(1 Pt A):7-18.
• [43] A new in vitro method for identifying chemical sensitizers combining peptide binding with ARE/EpRE-mediated gene expression in human skin cells. Cutan Ocul Toxicol. 2010 Sep;29(3):171-92.
• [44] Arsenic trioxide (ATO) influences the gene expression of metallothioneins in human glioblastoma cells. Biol Trace Elem Res. 2012 Dec;149(3):331-9.
• [45] Gene expression changes in human small airway epithelial cells exposed to Delta9-tetrahydrocannabinol. Toxicol Lett. 2005 Aug 14;158(2):95-107.
• [46] Integrative omics data analyses of repeated dose toxicity of valproic acid in vitro reveal new mechanisms of steatosis induction. Toxicology. 2018 Jan 15;393:160-170.
• [47] Zoledronate dysregulates fatty acid metabolism in renal tubular epithelial cells to induce nephrotoxicity. Arch Toxicol. 2018 Jan;92(1):469-485.
• [48] Identification of mechanisms of action of bisphenol a-induced human preadipocyte differentiation by transcriptional profiling. Obesity (Silver Spring). 2014 Nov;22(11):2333-43.
• [49] Physiological and toxicological transcriptome changes in HepG2 cells exposed to copper. Physiol Genomics. 2009 Aug 7;38(3):386-401.
• [50] Acute hypersensitivity of pluripotent testicular cancer-derived embryonal carcinoma to low-dose 5-aza deoxycytidine is associated with global DNA Damage-associated p53 activation, anti-pluripotency and DNA demethylation. PLoS One. 2012;7(12):e53003. doi: 10.1371/journal.pone.0053003. Epub 2012 Dec 27.
• [51] Cannabidiol induces antioxidant pathways in keratinocytes by targeting BACH1. Redox Biol. 2020 Jan;28:101321. doi: 10.1016/j.redox.2019.101321. Epub 2019 Sep 5.
• [52] Comparison of phenotypic and transcriptomic effects of false-positive genotoxins, true genotoxins and non-genotoxins using HepG2 cells. Mutagenesis. 2011 Sep;26(5):593-604.
• [53] Phenotypic characterization of retinoic acid differentiated SH-SY5Y cells by transcriptional profiling. PLoS One. 2013 May 28;8(5):e63862.
• [54] Robustness testing and optimization of an adverse outcome pathway on cholestatic liver injury. Arch Toxicol. 2020 Apr;94(4):1151-1172. doi: 10.1007/s00204-020-02691-9. Epub 2020 Mar 10.
• [55] Endoplasmic reticulum stress and MAPK signaling pathway activation underlie leflunomide-induced toxicity in HepG2 Cells. Toxicology. 2017 Dec 1;392:11-21.
• [56] Comparison of HepG2 and HepaRG by whole-genome gene expression analysis for the purpose of chemical hazard identification. Toxicol Sci. 2010 May;115(1):66-79.
• [57] Time series analysis of oxidative stress response patterns in HepG2: a toxicogenomics approach. Toxicology. 2013 Apr 5;306:24-34.
• [58] Molecular mechanisms of hepatotoxic cholestasis by clavulanic acid: Role of NRF2 and FXR pathways. Food Chem Toxicol. 2021 Dec;158:112664. doi: 10.1016/j.fct.2021.112664. Epub 2021 Nov 9.
• [59] Transcriptomic analysis of untreated and drug-treated differentiated HepaRG cells over a 2-week period. Toxicol In Vitro. 2015 Dec 25;30(1 Pt A):27-35.
• [60] Identification of approved drugs as potent inhibitors of pregnane X receptor activation with differential receptor interaction profiles. Arch Toxicol. 2018 Apr;92(4):1435-1451.
• [61] Characterization of drug-specific signaling between primary human hepatocytes and immune cells. Toxicol Sci. 2017 Jul 1;158(1):76-89.
• [62] Keratinocyte-derived IL-36gama plays a role in hydroquinone-induced chemical leukoderma through inhibition of melanogenesis in human epidermal melanocytes. Arch Toxicol. 2019 Aug;93(8):2307-2320.
• [63] Oxidative stress mechanisms do not discriminate between genotoxic and nongenotoxic liver carcinogens. Chem Res Toxicol. 2015 Aug 17;28(8):1636-46.
• [64] Integrative "-Omics" analysis in primary human hepatocytes unravels persistent mechanisms of cyclosporine A-induced cholestasis. Chem Res Toxicol. 2016 Dec 19;29(12):2164-2174.
• [65] Mechanism of cisplatin proximal tubule toxicity revealed by integrating transcriptomics, proteomics, metabolomics and biokinetics. Toxicol In Vitro. 2015 Dec 25;30(1 Pt A):117-27.
• [66] Cytotoxic Effects of Cannabinoids on Human HT-29 Colorectal Adenocarcinoma Cells: Different Mechanisms of THC, CBD, and CB83. Int J Mol Sci. 2020 Aug 1;21(15):5533. doi: 10.3390/ijms21155533.
• [67] Comparison of characteristics of peroxide-conditioned immortal human lens-epithelial cell lines with their murine counterparts. Exp Eye Res. 2004 Sep;79(3):411-7.
• [68] Quercetin modulates Nrf2 and glutathione-related defenses in HepG2 cells: Involvement of p38. Chem Biol Interact. 2012 Jan 25;195(2):154-64.
• [69] Pharmacotoxicology of clinically-relevant concentrations of obeticholic acid in an organotypic human hepatocyte system. Toxicol In Vitro. 2017 Mar;39:93-103.
• [70] Glutathione depletion in antioxidant defense of differentiated NT2-LHON cybrids. Neurobiol Dis. 2007 Mar;25(3):536-44.
• [71] An approach to elucidate potential mechanism of renal toxicity of arsenic trioxide. Exp Hematol. 2007 Feb;35(2):252-62.
• [72] Selenium and vitamin E: cell type- and intervention-specific tissue effects in prostate cancer. J Natl Cancer Inst. 2009 Mar 4;101(5):306-20.
• [73] Fumarate Mediates a Chronic Proliferative Signal in Fumarate Hydratase-Inactivated Cancer Cells by Increasing Transcription and Translation of Ferritin Genes. Mol Cell Biol. 2017 May 16;37(11):e00079-17. doi: 10.1128/MCB.00079-17. Print 2017 Jun 1.
• [74] Systems analysis of transcriptome and proteome in retinoic acid/arsenic trioxide-induced cell differentiation/apoptosis of promyelocytic leukemia. Proc Natl Acad Sci U S A. 2005 May 24;102(21):7653-8.
• [75] Essential role of cell cycle regulatory genes p21 and p27 expression in inhibition of breast cancer cells by arsenic trioxide. Med Oncol. 2011 Dec;28(4):1225-54.
• [76] Human embryonic stem cell-derived test systems for developmental neurotoxicity: a transcriptomics approach. Arch Toxicol. 2013 Jan;87(1):123-43.
• [77] Quantitative proteomics reveals a broad-spectrum antiviral property of ivermectin, benefiting for COVID-19 treatment. J Cell Physiol. 2021 Apr;236(4):2959-2975. doi: 10.1002/jcp.30055. Epub 2020 Sep 22.
• [78] Comparison of replicative senescence and stress-induced premature senescence combining differential display and low-density DNA arrays. FEBS Lett. 2005 Jul 4;579(17):3651-9. doi: 10.1016/j.febslet.2005.05.056.
• [79] Dexamethasone and the inflammatory response in explants of human omental adipose tissue. Mol Cell Endocrinol. 2010 Feb 5;315(1-2):292-8.
• [80] Inhibiting Heat Shock Proteins Can Potentiate the Cytotoxic Effect of Cannabidiol in Human Glioma Cells. Anticancer Res. 2015 Nov;35(11):5827-37.
• [81] Calcium pantothenate modulates gene expression in proliferating human dermal fibroblasts. Exp Dermatol. 2009 Nov;18(11):969-78. doi: 10.1111/j.1600-0625.2009.00884.x. Epub 2009 Apr 8.
• [82] Protective role of HO-1 for alcohol-dependent liver damage. Dig Dis. 2010;28(6):792-8. doi: 10.1159/000324287. Epub 2011 Apr 27.
• [83] ERE-independent ERalpha target genes differentially expressed in human breast tumors. Mol Cell Endocrinol. 2005 Dec 21;245(1-2):53-9. doi: 10.1016/j.mce.2005.10.003. Epub 2005 Nov 17.
• [84] Neuroprotective effects of glucomoringin-isothiocyanate against H(2)O(2)-Induced cytotoxicity in neuroblastoma (SH-SY5Y) cells. Neurotoxicology. 2019 Dec;75:89-104. doi: 10.1016/j.neuro.2019.09.008. Epub 2019 Sep 12.
• [85] High selenium status in individuals exposed to arsenic through coal-burning in Shaanxi (PR of China) modulates antioxidant enzymes, heme oxygenase-1 and DNA damage. Clin Chim Acta. 2010 Sep 6;411(17-18):1312-8.
• [86] Dimethyl Fumarate Inhibits the Nuclear Factor B Pathway in Breast Cancer Cells by Covalent Modification of p65 Protein. J Biol Chem. 2016 Feb 12;291(7):3639-47. doi: 10.1074/jbc.M115.679704. Epub 2015 Dec 18.
• [87] Combination treatment with arsenic trioxide and sulindac enhances apoptotic cell death in lung cancer cells via activation of oxidative stress and mitogen-activated protein kinases. Oncol Rep. 2008 Aug;20(2):379-84.
• [88] Functional gene expression profile underlying methotrexate-induced senescence in human colon cancer cells. Tumour Biol. 2011 Oct;32(5):965-76.
• [89] Predictive toxicology using systemic biology and liver microfluidic "on chip" approaches: application to acetaminophen injury. Toxicol Appl Pharmacol. 2012 Mar 15;259(3):270-80.
• [90] Cannabidiol Displays Proteomic Similarities to Antipsychotics in Cuprizone-Exposed Human Oligodendrocytic Cell Line MO3.13. Front Mol Neurosci. 2021 May 28;14:673144. doi: 10.3389/fnmol.2021.673144. eCollection 2021.
• [91] Arsenite and cadmium promote the development of mammary tumors. Carcinogenesis. 2020 Jul 14;41(7):1005-1014. doi: 10.1093/carcin/bgz176.
• [92] Retinoic acid and its 4-oxo metabolites are functionally active in human skin cells in vitro. J Invest Dermatol. 2005 Jul;125(1):143-53.
• [93] Temporal changes in gene expression in the skin of patients treated with isotretinoin provide insight into its mechanism of action. Dermatoendocrinol. 2009 May;1(3):177-87.
• [94] Isoniazid-induced apoptosis in HepG2 cells: generation of oxidative stress and Bcl-2 down-regulation. Toxicol Mech Methods. 2010 Jun;20(5):242-51. doi: 10.3109/15376511003793325.
• [95] Transcriptional and Metabolic Dissection of ATRA-Induced Granulocytic Differentiation in NB4 Acute Promyelocytic Leukemia Cells. Cells. 2020 Nov 5;9(11):2423. doi: 10.3390/cells9112423.
• [96] Classification of heavy-metal toxicity by human DNA microarray analysis. Environ Sci Technol. 2007 May 15;41(10):3769-74.
• [97] Posttranslational glutathiolation of aldose reductase (AKR1B1): a possible mechanism of protein recovery from S-nitrosylation. Chem Biol Interact. 2009 Mar 16;178(1-3):250-8. doi: 10.1016/j.cbi.2008.11.007. Epub 2008 Nov 18.
• [98] Integrating multiple omics to unravel mechanisms of Cyclosporin A induced hepatotoxicity in vitro. Toxicol In Vitro. 2015 Apr;29(3):489-501.
• [99] Interleukin-19 as a translational indicator of renal injury. Arch Toxicol. 2015 Jan;89(1):101-6.
• [100] Temozolomide induces activation of Wnt/-catenin signaling in glioma cells via PI3K/Akt pathway: implications in glioma therapy. Cell Biol Toxicol. 2020 Jun;36(3):273-278. doi: 10.1007/s10565-019-09502-7. Epub 2019 Nov 22.
• [101] Functional cardiotoxicity assessment of cosmetic compounds using human-induced pluripotent stem cell-derived cardiomyocytes. Arch Toxicol. 2018 Jan;92(1):371-381.
• [102] Gypenosides protect retinal pigment epithelium cells from oxidative stress. Food Chem Toxicol. 2018 Feb;112:76-85.
• [103] Enhanced cytotoxicity of bioreductive antitumor agents with dimethyl fumarate in human glioblastoma cells. Anticancer Drugs. 2005 Feb;16(2):167-74.
• [104] Growth-suppressive effect of non-steroidal anti-inflammatory drugs on 11 colon-cancer cell lines and fluorescence differential display of genes whose expression is influenced by sulindac. Int J Cancer. 2000 Dec 15;88(6):873-80. doi: 10.1002/1097-0215(20001215)88:6<873::aid-ijc6>3.0.co;2-b.
• [105] Simvastatin protects dopaminergic neurons against MPP+-induced oxidative stress and regulates the endogenous anti-oxidant system through ERK. Cell Physiol Biochem. 2018;51(4):1957-1968.
• [106] P450 3A-catalyzed O-dealkylation of lapatinib induces mitochondrial stress and activates Nrf2. Chem Res Toxicol. 2016 May 16;29(5):784-96.
• [107] Induction of human NAD(P)H:quinone oxidoreductase (NQO1) gene expression by the flavonol quercetin. Toxicol Lett. 2001 Feb 3;119(1):49-57.
• [108] Rofecoxib modulates multiple gene expression pathways in a clinical model of acute inflammatory pain. Pain. 2007 Mar;128(1-2):136-47.
• [109] Microarray analysis of H2O2-, HNE-, or tBH-treated ARPE-19 cells. Free Radic Biol Med. 2002 Nov 15;33(10):1419-32.
• [110] The Isoniazid Metabolites Hydrazine and Pyridoxal Isonicotinoyl Hydrazone Modulate Heme Biosynthesis. Toxicol Sci. 2019 Mar 1;168(1):209-224. doi: 10.1093/toxsci/kfy294.
• [111] Bringing in vitro analysis closer to in vivo: studying doxorubicin toxicity and associated mechanisms in 3D human microtissues with PBPK-based dose modelling. Toxicol Lett. 2018 Sep 15;294:184-192.
• [112] Type 5 17beta-hydroxysteroid dehydrogenase/prostaglandin F synthase (AKR1C3): role in breast cancer and inhibition by non-steroidal anti-inflammatory drug analogs. Chem Biol Interact. 2009 Mar 16;178(1-3):221-7.
• [113] Substrate specificity of human 3(20)alpha-hydroxysteroid dehydrogenase for neurosteroids and its inhibition by benzodiazepines. Biol Pharm Bull. 2002 Apr;25(4):441-5.
• [114] Progestins as inhibitors of the human 20-ketosteroid reductases, AKR1C1 and AKR1C3. Chem Biol Interact. 2011 May 30;191(1-3):227-33.
• [115] In-vivo effects of simvastatin and rosuvastatin on global gene expression in peripheral blood leucocytes in a human inflammation model. Pharmacogenet Genomics. 2008 Feb;18(2):109-20.
• [116] AKR1C3 as a potential target for the inhibitory effect of dietary flavonoids. Chem Biol Interact. 2009 Mar 16;178(1-3):138-44.
• [117] Changes in gene expression profiles of multiple myeloma cells induced by arsenic trioxide (ATO): possible mechanisms to explain ATO resistance in vivo. Br J Haematol. 2005 Mar;128(5):636-44.
• [118] Blood cell oxidative stress precedes hemolysis in whole blood-liver slice co-cultures of rat, dog, and human tissues. Toxicol Appl Pharmacol. 2010 May 1;244(3):354-65. doi: 10.1016/j.taap.2010.01.017. Epub 2010 Feb 6.
• [119] Induction of multidrug resistance proteins MRP1 and MRP3 and gamma-glutamylcysteine synthetase gene expression by nonsteroidal anti-inflammatory drugs in human colon cancer cells. Biochem Biophys Res Commun. 2002 Feb 8;290(5):1427-33. doi: 10.1006/bbrc.2002.6367.
• [120] Flavonoids increase the intracellular glutathione level by transactivation of the gamma-glutamylcysteine synthetase catalytical subunit promoter. Free Radic Biol Med. 2002 Mar 1;32(5):386-93. doi: 10.1016/s0891-5849(01)00812-7.
• [121] Effects of ciglitazone and troglitazone on the proliferation of human stomach cancer cells. World J Gastroenterol. 2009 Jan 21;15(3):310-20.
• [122] Glycidamide and cis-2-butene-1,4-dial (BDA) as potential carcinogens and promoters of liver cancer - An in vitro study. Food Chem Toxicol. 2022 Aug;166:113251. doi: 10.1016/j.fct.2022.113251. Epub 2022 Jun 21.
• [123] Darinaparsin induces a unique cellular response and is active in an arsenic trioxide-resistant myeloma cell line. Mol Cancer Ther. 2009 May;8(5):1197-206.
• [124] Oxidative stress modulates theophylline effects on steroid responsiveness. Biochem Biophys Res Commun. 2008 Dec 19;377(3):797-802.
• [125] Essential role of Nrf2 in keratinocyte protection from UVA by quercetin. Biochem Biophys Res Commun. 2009 Sep 11;387(1):109-14. doi: 10.1016/j.bbrc.2009.06.136. Epub 2009 Jul 1.
• [126] Comparison of base-line and chemical-induced transcriptomic responses in HepaRG and RPTEC/TERT1 cells using TempO-Seq. Arch Toxicol. 2018 Aug;92(8):2517-2531.
• [127] An in vitro skin sensitization assay termed EpiSensA for broad sets of chemicals including lipophilic chemicals and pre/pro-haptens. Toxicol In Vitro. 2017 Apr;40:11-25. doi: 10.1016/j.tiv.2016.12.005. Epub 2016 Dec 10.
• [128] Differential modulation of PI3-kinase/Akt pathway during all-trans retinoic acid- and Am80-induced HL-60 cell differentiation revealed by DNA microarray analysis. Biochem Pharmacol. 2004 Dec 1;68(11):2177-86.
• [129] Defenses against oxidation in human erythrocytes: role of glutathione reductase in the activation of glucose decarboxylation by hemolytic drugs. J Lab Clin Med. 1991 Apr;117(4):325-31.
• [130] Progestin effects on expression of AKR1C1-AKR1C3, SRD5A1 and PGR in the Z-12 endometriotic epithelial cell line. Chem Biol Interact. 2013 Feb 25;202(1-3):218-25.
• [131] Isoform-specific induction of a human aldo-keto reductase by polycyclic aromatic hydrocarbons (PAHs), electrophiles, and oxidative stress: implications for the alternative pathway of PAH activation catalyzed by human dihydrodiol dehydrogenase. Cancer Res. 1999 Feb 1;59(3):607-14.
• [132] Simvastatin inactivates beta1-integrin and extracellular signal-related kinase signaling and inhibits cell proliferation in head and neck squamous cell carcinoma cells. Cancer Sci. 2007 Jun;98(6):890-9.
• [133] Initro inhibition of AKR1Cs by sulphonylureas and the structural basis. Chem Biol Interact. 2015 Oct 5;240:310-5.
• [134] Human prostaglandin reductase 1 (PGR1): Substrate specificity, inhibitor analysis and site-directed mutagenesis. Chem Biol Interact. 2015 Jun 5;234:105-13.
• [135] The neuroprotective action of the mood stabilizing drugs lithium chloride and sodium valproate is mediated through the up-regulation of the homeodomain protein Six1. Toxicol Appl Pharmacol. 2009 Feb 15;235(1):124-34.
• [136] Mapping the dynamics of Nrf2 antioxidant and NFB inflammatory responses by soft electrophilic chemicals in human liver cells defines the transition from adaptive to adverse responses. Toxicol In Vitro. 2022 Oct;84:105419. doi: 10.1016/j.tiv.2022.105419. Epub 2022 Jun 17.
• [137] Transcriptome-based functional classifiers for direct immunotoxicity. Arch Toxicol. 2014 Mar;88(3):673-89.
• [138] Low doses of cisplatin induce gene alterations, cell cycle arrest, and apoptosis in human promyelocytic leukemia cells. Biomark Insights. 2016 Aug 24;11:113-21.
• [139] An evaluation of myeloperoxidase-mediated bio-activation of NSAIDs in promyelocytic leukemia (HL-60) cells for potential cytotoxic selectivity. Toxicol Lett. 2017 Oct 5;280:48-56.
• [140] Differentiation between stoichiometric and anticatalytic antioxidant properties of benzoic acid analogues: a structure/redox potential relationship study. Chem Biol Interact. 2013 Nov 25;206(2):194-203.
• [141] Suppression of RAGE as a basis of simvastatin-dependent plaque stabilization in type 2 diabetes. Arterioscler Thromb Vasc Biol. 2006 Dec;26(12):2716-23.
• [142] Effect of anti-rheumatic drugs on the release of lysosomal enzymes from human leukocytes. Z Rheumatol. 1984 Jan-Feb;43(1):23-6.
• [143] Benzodithiophenes induce differentiation and apoptosis in human leukemia cells. Cancer Res. 2005 Sep 1;65(17):7847-55. doi: 10.1158/0008-5472.CAN-05-1053.
• [144] Inhibition of oxidation activity of myeloperoxidase (MPO) by propylthiouracil (PTU) and anti-MPO antibodies from patients with PTU-induced vasculitis. Clin Immunol. 2007 Feb;122(2):187-93. doi: 10.1016/j.clim.2006.09.011. Epub 2006 Oct 27.
• [145] Role of antioxidant systems in human androgen-independent prostate cancer cells. Prostate. 2000 May 1;43(2):144-9. doi: 10.1002/(sici)1097-0045(20000501)43:2<144::aid-pros9>3.0.co;2-h.
• [146] Selenium deficiency alters epithelial cell morphology and responses to influenza. Free Radic Biol Med. 2007 Jun 15;42(12):1826-37.
• [147] Hepatocellular peroxisomes in human alcoholic and drug-induced hepatitis: a quantitative study. Hepatology. 1991 Nov;14(5):811-7.
• [148] Antioxidant enzyme and malondialdehyde values in social phobia before and after citalopram treatment. Eur Arch Psychiatry Clin Neurosci. 2004 Aug;254(4):231-5.
• [149] The contribution of methotrexate exposure and host factors on transcriptional variance in human liver. Toxicol Sci. 2007 Jun;97(2):582-94.
• [150] The effect of statins on lipids peroxidation and activities of antioxidants enzymes in patients with dyslipidemia. Przegl Lek. 2006;63(9):738-42.
• [151] Acetaminophen-induced proliferation of estrogen-responsive breast cancer cells is associated with increases in c-myc RNA expression and NF-kappaB activity. Toxicol Sci. 2002 Apr;66(2):233-43. doi: 10.1093/toxsci/66.2.233.
• [152] Sertraline induces endoplasmic reticulum stress in hepatic cells. Toxicology. 2014 Aug 1;322:78-88. doi: 10.1016/j.tox.2014.05.007. Epub 2014 May 24.
• [153] Estrogen regulation in human breast cancer cells of new downstream gene targets involved in estrogen metabolism, cell proliferation and cell transformation. J Mol Endocrinol. 2004 Apr;32(2):397-414.
• [154] ZD1839 induces p15INK4b and causes G1 arrest by inhibiting the mitogen-activated protein kinase/extracellular signal-regulated kinase pathway. Mol Cancer Ther. 2007 May;6(5):1579-87. doi: 10.1158/1535-7163.MCT-06-0814.
• [155] Arsenic suppresses gene expression in promyelocytic leukemia cells partly through Sp1 oxidation. Blood. 2005 Jul 1;106(1):304-10.
• [156] Selenite and selenomethionine promote HL-60 cell cycle progression. J Nutr. 2002 Apr;132(4):674-9. doi: 10.1093/jn/132.4.674.
• [157] Ribavirin augments doxorubicin's efficacy in human hepatocellular carcinoma through inhibiting doxorubicin-induced eIF4E activation. J Biochem Mol Toxicol. 2018 Jan;32(1). doi: 10.1002/jbt.22007. Epub 2017 Nov 7.
• [158] Combination small molecule MEK and PI3K inhibition enhances uveal melanoma cell death in a mutant GNAQ- and GNA11-dependent manner. Clin Cancer Res. 2012 Aug 15;18(16):4345-55. doi: 10.1158/1078-0432.CCR-11-3227. Epub 2012 Jun 25.
• [159] Novel detection and differential utilization of a c-myc transcriptional block in colon cancer chemoprevention. Cancer Res. 2002 Nov 1;62(21):6006-10.
• [160] An in vitro coculture system of human peripheral blood mononuclear cells with hepatocellular carcinoma-derived cells for predicting drug-induced liver injury. Arch Toxicol. 2021 Jan;95(1):149-168. doi: 10.1007/s00204-020-02882-4. Epub 2020 Aug 20.
• [161] Oxidative Stress Alters miRNA and Gene Expression Profiles in Villous First Trimester Trophoblasts. Biomed Res Int. 2015;2015:257090. doi: 10.1155/2015/257090. Epub 2015 Aug 3.
• [162] Quercetin potentiates apoptosis by inhibiting nuclear factor-kappaB signaling in H460 lung cancer cells. Biol Pharm Bull. 2013;36(6):944-51. doi: 10.1248/bpb.b12-01004.
• [163] Monomeric and oligomeric flavanols maintain the endogenous glucocorticoid response in human macrophages in pro-oxidant conditions in vitro. Chem Biol Interact. 2018 Aug 1;291:237-244.
• [164] Nicotine up-regulates IL-8 expression in human gingival epithelial cells following stimulation with IL-1 or P. gingivalis lipopolysaccharide via nicotinic acetylcholine receptor signalling. Arch Oral Biol. 2012 May;57(5):483-90. doi: 10.1016/j.archoralbio.2011.10.007. Epub 2011 Nov 25.
• [165] Ca(2+) Signaling and IL-8 Secretion in Human Testicular Peritubular Cells Involve the Cation Channel TRPV2. Int J Mol Sci. 2018 Sep 19;19(9):2829. doi: 10.3390/ijms19092829.
• [166] Nitrogen mustard prevents transport of Fra-1 into the nucleus to promote c-Fos- and FosB-dependent IL-8 induction in injured mouse epidermis. Toxicol Lett. 2020 Feb 1;319:256-263. doi: 10.1016/j.toxlet.2019.10.006. Epub 2019 Oct 19.
• [167] Nitric oxide synthase inhibitors attenuate ozone-induced airway inflammation in guinea pigs. Possible role of interleukin-8. Am J Respir Crit Care Med. 2000 Jan;161(1):249-56. doi: 10.1164/ajrccm.161.1.9804096.
• [168] Ouabain at pathological concentrations might induce damage in human vascular endothelial cells. Acta Pharmacol Sin. 2006 Feb;27(2):165-72. doi: 10.1111/j.1745-7254.2006.00244.x.
• [169] Controlled diesel exhaust and allergen coexposure modulates microRNA and gene expression in humans: Effects on inflammatory lung markers. J Allergy Clin Immunol. 2016 Dec;138(6):1690-1700. doi: 10.1016/j.jaci.2016.02.038. Epub 2016 Apr 24.
• [170] Transcriptional signature of human macrophages exposed to the environmental contaminant benzo(a)pyrene. Toxicol Sci. 2010 Apr;114(2):247-59.
• [171] Cell-based two-dimensional morphological assessment system to predict cancer drug-induced cardiotoxicity using human induced pluripotent stem cell-derived cardiomyocytes. Toxicol Appl Pharmacol. 2019 Nov 15;383:114761. doi: 10.1016/j.taap.2019.114761. Epub 2019 Sep 15.
• [172] Clarifying off-target effects for torcetrapib using network pharmacology and reverse docking approach. BMC Syst Biol. 2012 Dec 10;6:152.
• [173] Large-scale in silico and microarray-based identification of direct 1,25-dihydroxyvitamin D3 target genes. Mol Endocrinol. 2005 Nov;19(11):2685-95.
• [174] Identification of novel low-dose bisphenol a targets in human foreskin fibroblast cells derived from hypospadias patients. PLoS One. 2012;7(5):e36711. doi: 10.1371/journal.pone.0036711. Epub 2012 May 4.
• [175] Grouping of histone deacetylase inhibitors and other toxicants disturbing neural crest migration by transcriptional profiling. Neurotoxicology. 2015 Sep;50:56-70.
• [176] Expression profiling in squamous carcinoma cells reveals pleiotropic effects of vitamin D3 analog EB1089 signaling on cell proliferation, differentiation, and immune system regulation. Mol Endocrinol. 2002 Jun;16(6):1243-56.
• [177] Coumarins from Angelica decursiva inhibit -glucosidase activity and protein tyrosine phosphatase 1B. Chem Biol Interact. 2016 May 25;252:93-101. doi: 10.1016/j.cbi.2016.04.020. Epub 2016 Apr 13.
• [178] Proteomic analysis of the cellular response to a potent sensitiser unveils the dynamics of haptenation in living cells. Toxicology. 2020 Dec 1;445:152603. doi: 10.1016/j.tox.2020.152603. Epub 2020 Sep 28.
• [179] Effect of aflatoxin B(1), benzo[a]pyrene, and methapyrilene on transcriptomic and epigenetic alterations in human liver HepaRG cells. Food Chem Toxicol. 2018 Nov;121:214-223. doi: 10.1016/j.fct.2018.08.034. Epub 2018 Aug 26.
• [180] The nonsteroidal anti-inflammatory drugs aspirin and indomethacin attenuate beta-catenin/TCF-4 signaling. Oncogene. 2001 Feb 1;20(5):645-53. doi: 10.1038/sj.onc.1204123.
• [181] Novel mechanism of cannabidiol-induced apoptosis in breast cancer cell lines. Breast. 2018 Oct;41:34-41. doi: 10.1016/j.breast.2018.06.009. Epub 2018 Jun 22.
• [182] -Carotene Induces Apoptosis in Human Esophageal Squamous Cell Carcinoma Cell Lines via the Cav-1/AKT/NF-B Signaling Pathway. J Biochem Mol Toxicol. 2016 Mar;30(3):148-57. doi: 10.1002/jbt.21773. Epub 2016 Jan 6.
• [183] Cross-talk between non-genomic and genomic signalling pathways--distinct effect profiles of environmental estrogens. Toxicol Appl Pharmacol. 2010 Jun 1;245(2):160-70. doi: 10.1016/j.taap.2010.02.015. Epub 2010 Mar 4.
• [184] Dasatinib (BMS-354825) selectively induces apoptosis in lung cancer cells dependent on epidermal growth factor receptor signaling for survival. Cancer Res. 2006 Jun 1;66(11):5542-8. doi: 10.1158/0008-5472.CAN-05-4620.
• [185] BMN 673 (talazoparib): A potent PARP inhibitor for triple negative breast cancer with different genetic profile. J Biochem Mol Toxicol. 2019 May;33(5):e22286. doi: 10.1002/jbt.22286. Epub 2019 Jan 23.
• [186] Resveratrol attenuates senescence of adipose-derived mesenchymal stem cells and restores their paracrine effects on promoting insulin secretion of INS-1 cells through Pim-1. Eur Rev Med Pharmacol Sci. 2016;20(6):1203-13.
• [187] Cell cycle effects of nonsteroidal anti-inflammatory drugs and enhanced growth inhibition in combination with gemcitabine in pancreatic carcinoma cells. J Pharmacol Exp Ther. 2001 Sep;298(3):976-85.
• [188] Development of a neural teratogenicity test based on human embryonic stem cells: response to retinoic acid exposure. Toxicol Sci. 2011 Dec;124(2):370-7.
• [189] Proteomic profile of aminoglutethimide-induced apoptosis in HL-60 cells: role of myeloperoxidase and arylamine free radicals. Chem Biol Interact. 2015 Sep 5;239:129-38.
• [190] Proteomic analysis revealed association of aberrant ROS signaling with suberoylanilide hydroxamic acid-induced autophagy in Jurkat T-leukemia cells. Autophagy. 2010 Aug;6(6):711-24. doi: 10.4161/auto.6.6.12397. Epub 2010 Aug 17.
• [191] Gene expression profiling of 30 cancer cell lines predicts resistance towards 11 anticancer drugs at clinically achieved concentrations. Int J Cancer. 2006 Apr 1;118(7):1699-712. doi: 10.1002/ijc.21570.
• [192] Rifampin Regulation of Drug Transporters Gene Expression and the Association of MicroRNAs in Human Hepatocytes. Front Pharmacol. 2016 Apr 26;7:111.
• [193] In vitro and pharmacophore-based discovery of novel hPEPT1 inhibitors. Pharm Res. 2005 Apr;22(4):512-7. doi: 10.1007/s11095-005-2505-y. Epub 2005 Apr 7.
• [194] Enhancement effect of resveratrol on the intestinal absorption of bestatin by regulating PEPT1, MDR1 and MRP2 in vivo and in vitro. Int J Pharm. 2015 Nov 10;495(1):588-598. doi: 10.1016/j.ijpharm.2015.09.042. Epub 2015 Sep 21.
• [195] Affinity and translocation relationships via hPEPT1 of H-X aa-Ser-OH dipeptides: evaluation of H-Phe-Ser-OH as a pro-moiety for ibuprofen and benzoic acid prodrugs. Eur J Pharm Biopharm. 2011 Feb;77(2):327-31. doi: 10.1016/j.ejpb.2010.12.009. Epub 2010 Dec 13.
• [196] Gene Expression Regulation and Pathway Analysis After Valproic Acid and Carbamazepine Exposure in a Human Embryonic Stem Cell-Based Neurodevelopmental Toxicity Assay. Toxicol Sci. 2015 Aug;146(2):311-20. doi: 10.1093/toxsci/kfv094. Epub 2015 May 15.
• [197] Severe villus atrophy and chronic malabsorption induced by azathioprine. Gastroenterology. 2003 Jun;124(7):1950-7.
• [198] Cyp2a6 is a principal enzyme involved in hydroxylation of 1,7-dimethylxanthine, a main caffeine metabolite, in humans. Drug Metab Dispos. 2005 Sep;33(9):1361-6. doi: 10.1124/dmd.105.004796. Epub 2005 Jun 24.
• [199] Mimicking gene defects to treat drug dependence. Ann N Y Acad Sci. 2000;909:233-46. doi: 10.1111/j.1749-6632.2000.tb06685.x.
• [200] Expression of CYP2A6 in tumor cells augments cellular sensitivity to tegafur. Jpn J Cancer Res. 2001 May;92(5):524-8. doi: 10.1111/j.1349-7006.2001.tb01125.x.
• [201] CYP1A1/1B1 and CYP2A6/2A13 activity is conserved in cultures of differentiated primary human tracheobronchial epithelial cells. Toxicol In Vitro. 2011 Jun;25(4):922-9.
• [202] Multiple microRNAs function as self-protective modules in acetaminophen-induced hepatotoxicity in humans. Arch Toxicol. 2018 Feb;92(2):845-858.
• [203] Isoform-specific regulation of cytochromes P450 expression by estradiol and progesterone. Drug Metab Dispos. 2013 Feb;41(2):263-9.
• [204] Measurement of 4-hydroxylation of ifosfamide in human liver microsomes using the estimation of free and protein-bound acrolein and codetermination of keto- and carboxyifosfamide. J Cancer Res Clin Oncol. 2002 Jul;128(7):385-92.
• [205] Integrated 'omics analysis reveals new drug-induced mitochondrial perturbations in human hepatocytes. Toxicol Lett. 2018 Jun 1;289:1-13.
• [206] Deactivation of anti-cancer drug letrozole to a carbinol metabolite by polymorphic cytochrome P450 2A6 in human liver microsomes. Xenobiotica. 2009 Nov;39(11):795-802. doi: 10.3109/00498250903171395.
• [207] A novel single nucleotide polymorphism altering stability and activity of CYP2a6. Biochem Biophys Res Commun. 2001 Mar 2;281(3):810-4. doi: 10.1006/bbrc.2001.4422.
• [208] Increased organophosphate scavenging in a butyrylcholinesterase mutant. Chem Biol Interact. 2008 Sep 25;175(1-3):376-9. doi: 10.1016/j.cbi.2008.04.012. Epub 2008 Apr 22.
• [209] Comparative effects of cationic triarylmethane, phenoxazine and phenothiazine dyes on horse serum butyrylcholinesterase. Arch Biochem Biophys. 2008 Oct 15;478(2):201-5.
• [210] Lichens of parmelioid clade as promising multitarget neuroprotective agents. Chem Res Toxicol. 2019 Jun 17;32(6):1165-1177.
• [211] Potencies and selectivities of inhibitors of acetylcholinesterase and its molecular forms in normal and Alzheimer's disease brain. Acta Biol Hung. 2003;54(2):183-9. doi: 10.1556/ABiol.54.2003.2.7.
• [212] Response of the newborn to succinlycholine injection in homozygotic atypical mothers. Anesthesiology. 1975 Jul;43(1):115-6. doi: 10.1097/00000542-197507000-00028.
• [213] Cholinesterase inhibition by phenothiazine and nonphenothiazine antihistaminics: analysis of its postulated role in synergizing organophosphate toxicity. Toxicol Appl Pharmacol. 1975 Feb;31(2):179-90.
• [214] Qualitative defects of pseudocholinesterase activity. Anaesthesia. 1967 Jan;22(1):55-68.
• [215] Differential gene expression in human hepatocyte cell lines exposed to the antiretroviral agent zidovudine. Arch Toxicol. 2014 Mar;88(3):609-23. doi: 10.1007/s00204-013-1169-3. Epub 2013 Nov 30.
• [216] A transcriptome-based classifier to identify developmental toxicants by stem cell testing: design, validation and optimization for histone deacetylase inhibitors. Arch Toxicol. 2015 Sep;89(9):1599-618.
• [217] Expression profile analysis of colon cancer cells in response to sulindac or aspirin. Biochem Biophys Res Commun. 2002 Mar 29;292(2):498-512.
• [218] Modulation of butyrate transport in Caco-2 cells. Naunyn Schmiedebergs Arch Pharmacol. 2009 Apr;379(4):325-36. doi: 10.1007/s00210-008-0372-x. Epub 2008 Nov 21.